Description
Factor VIII:C Polyclonal Antibody – Affinity Purified – Biotinylated
Affinity’s Factor VIII:C Polyclonal Antibody – Affinity Purified – Biotinylated is the highest level of our biotin conjugated Factor VIII:C antibodies. During the Antigen Affinity Purification process the IgG has had any non-specific immunoglobulin fraction eliminated which enriches the specificity of the remaining immunoglobulin towards the target antigen. The result is a very high-purity product with a substantially higher titre than whole or purified IgG. Our Factor VIII:C Polyclonal Antibody – Affinity Purified – Biotinylated is provided in a solution of HEPES buffered saline containing 50% glycerol (v/v) and has been conjugated with Biotin as an enzyme reporter. This antibody is generally intended for use as labelled primary antibodies in applications such as immunoassay and immunoblotting.
Product Code: SAF8C-APBIO
Retail Product Size: 0.1mg vial
Host Animal: Sheep Anti-Human Factor VIII:C Polyclonal Antibody – Affinity Purified – Biotinylated
Species Cross Reactivity: View Chart
Product Datasheet: Factor VIII F8 Polyclonal Antibody - affinity purified Biotin conjugated anti-human sheep IgG
Description of Factor VIII
Factor VIII (formerly referred to as antihemophilic globulin and Factor VIII:C) is a large glycoprotein (320 kDa) that circulates in plasma at approximately 200 ng/ml. Synthesized in the liver, the majority of Factor VIII is cleaved during expression, resulting in a heterogeneous mixture of partially cleaved forms of FVIII ranging in size from 200-280 kDa. The FVIII is stabilized by association with von Willebrand Factor to form a FVIII-vWF complex required for the normal survival of FVIII in vivo (t1/2 of 8-12 hours).
F.VIII is a pro-cofactor that is activated through limited proteolysis by thrombin. In this process F.VIIIa dissociates from vWF to combine with activated Factor IX, calcium and a phospholipid surface where it is an essential cofactor in the assembly of the Factor X activator complex. Once dissociated from vWF, FVIIIa is susceptible to inactivation by activated Protein C and by non-enzymatic decay.
Hemophilia A is a congenital bleeding disorder resulting from an X-chromosome-linked deficiency of FVIII. The severity of the deficiency generally correlates with the severity of the disease. Some Hemophiliacs (~10%) produce a FVIII protein that is partially or totally inactive. The production of neutralizing antibodies to FVIII also occurs in 5-20% of Hemophiliacs 1-3.
References and Review
- Lollar P, Fay PJ, Fass DN; Factor VIII and Factor VIIIa. Methods in Enzymology, 222, pg 122, 1993.
- Hoyer, LW, Wyshock EG, Colman RW, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 109-133, J.B. Lippincott Co., Philadelphia, 1994.
- Pittman DD, Kaufman RJ. Structure-Function Relationships of Factor VIII Elucidated through Recombinant DNA Technology. Thromb. Haemostasis. 61:161-165, 1989.
